Impact and Tolerance of Immunosuppressive Treatments in Patients Living with HIV with Inflammatory or Autoimmune Diseases

Background: Patients living with HIV (PLWHIV) can develop autoimmune diseases (AD) needing immunosuppressive treatments (IST). This study aims to describe the impact of IST in PLWHIV. Methods: This was a multicentric retrospective observational study in six HIV referral centers on PLWHIV under IST for AD. Demographic factors, viral co-infections, immunovirological status before and under IST, infectious events, and their descriptions were collected and described focusing on infectious events, immunovirological variations, and IST effectiveness. Results: 9480 PLWHIV were screened for inclusion. Among them, 138 (1.5%) had a history of auto-immune disease, among which 32 (23%) received IST. There was mainly spondyloarthropathy (28%) and the most commonly used IST was methotrexate. The median follow-up under IST was 3.8 years (2.7; 5.9). There were 15 infectious events (0.5 events/individuals) concerning nine patients. At the last medical follow-up, 81% of these were in remission of their AD. Under IST, there was an increase in CD4 during follow-up (629 vs. 827 CD4/mm3, p = 0.04). No HIV virological failure was noted. Conclusions: This study supports a growing evidence base that IST can be used safely and effectively in PLWHIV with careful monitoring.

[1]  Madeleine Durand,et al.  Incidence of autoimmune diseases in people living with HIV compared to a matched population: a cohort study , 2020, Clinical Rheumatology.

[2]  M. Peluso,et al.  Outcomes of immunomodulatory and biologic therapy in people living with HIV: a report from two academic hospitals. , 2020, AIDS.

[3]  L. Dauchet,et al.  Fine‐scale geographical distribution and ecological risk factors for Crohn's disease in France (2007‐2014) , 2020, Alimentary pharmacology & therapeutics.

[4]  P. Goupille,et al.  CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis , 2019, British journal of clinical pharmacology.

[5]  J. Carey,et al.  Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis , 2018, Journal of clinical medicine.

[6]  I. García-Doval,et al.  Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study , 2018, The Journal of dermatological treatment.

[7]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[8]  R. Miller,et al.  Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals , 2017, International journal of STD & AIDS.

[9]  R. Green,et al.  Autoimmune hepatitis in patients with human immunodeficiency virus (HIV) , 2017, Medicine.

[10]  P. Sève,et al.  Autoimmune diseases and HIV infection , 2017, Medicine.

[11]  Marien González-Lorenzo,et al.  Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis , 2016, Expert opinion on drug safety.

[12]  C. Bingham,et al.  Rates of Serious Infections in HIV‐Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases , 2016, Arthritis care & research.

[13]  E. Lowenstein,et al.  Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. , 2016, Journal of the American Academy of Dermatology.

[14]  A. Alanio,et al.  Treatment with adalimumab for severe immune reconstitution inflammatory syndrome in an HIV-infected patient presenting with cryptococcal meningitis. , 2016, Medecine et maladies infectieuses.

[15]  M. Tsai,et al.  Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy. , 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[16]  M. Bower,et al.  Azathioprine can be safely used in HIV-infected individuals. , 2014, AIDS.

[17]  X. le Loët,et al.  Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept. , 2011, Rheumatology.

[18]  S. Agrawal,et al.  Mycophenolate: dual utility in rare conditions of HIV infection complicating lupus , 2010, Lupus.

[19]  B. Strober,et al.  Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. , 2010, Journal of the American Academy of Dermatology.

[20]  Amy M. Sitapati,et al.  Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Lauren E. Manning,et al.  Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  S. Forman,et al.  Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment. , 2008, Journal of Drugs in Dermatology.

[23]  J. Reveille,et al.  The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease , 2007, Annals of the rheumatic diseases.

[24]  P. Morlat,et al.  [Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic ant therapeutic difficulties]. , 2006, La Revue de medecine interne.

[25]  L. Calabrese,et al.  Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. , 2005, Seminars in arthritis and rheumatism.

[26]  J. Lacki,et al.  Quantitative changes in peripheral blood lymphocytes in erosive rheumatoid arthritis patients treated with methotrexate. Correlation with disease activity. , 1999, Journal of investigational allergology & clinical immunology.

[27]  T. Maurer,et al.  The use of methotrexate for treatment of psoriasis in patients with HIV infection. , 1994, Journal of the American Academy of Dermatology.

[28]  P. Chin-Hong.  Infectious and Other Complications of Immunobiologic Agents. , 2019, Topics in antiviral medicine.

[29]  B. Bhattarai,et al.  Rheumatic diseases in HIV-infected patients in the post-antiretroviral therapy era: a tertiary care center experience , 2018, Clinical Rheumatology.